Cargando…
Dupilumab in Inflammatory Skin Diseases: A Systematic Review
Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was ap...
Autores principales: | Olbrich, Henning, Sadik, Christian D., Ludwig, Ralf J., Thaçi, Diamant, Boch, Katharina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136243/ https://www.ncbi.nlm.nih.gov/pubmed/37189381 http://dx.doi.org/10.3390/biom13040634 |
Ejemplares similares
-
Cutaneous lupus erythematosus is associated with an increased risk of cardiac and vascular diseases: a large-scale, propensity-matched global retrospective cohort study
por: Olbrich, Henning, et al.
Publicado: (2023) -
Paradoxical improvement of life quality in the COVID-19 era in psoriasis patients
por: Boch, Katharina, et al.
Publicado: (2022) -
Healthcare Professional (HCP) and Patient Usability Evaluation and Preferences of Two Auto-injector Devices for Self-Injection of Biosimilars, SB4 and SB5: A Literature Review
por: Corominas, Héctor, et al.
Publicado: (2023) -
Real‐world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta‐analysis
por: Charles, David, et al.
Publicado: (2022) -
Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
por: Ujiie, Hideyuki, et al.
Publicado: (2022)